Nexentis Technologies Inc (NXTS) Stock AnalysisNXTSStock AnalysisNexentis Technologies Inc

Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity. It operates in the Basic Materials sector.

Nexentis Technologies Inc is currently trading at $1.84, with a 1-year change of -78.45%, indicating substantial losses over the past year. The RSI is at 44.79, suggesting the stock is nearing oversold territory, but not yet a strong buy signal. The forward P/E ratio is 0, indicating uncertainty in future earnings, and the gross margin is 61.23%, which is a positive sign. However, the main risk is the significant net income loss of -$6,580,000 in Q1 2026, which raises concerns about the company's profitability.